Grants / Department of Health and Human Services / Centers for Disease Control - CGH

CDC-RFA-GH22-2272: Informing global polio eradication efforts through innovative modeling approaches

Closed Closed May 6, 2022 Opportunity CDC-RFA-GH22-2272 ☆ Save

This grant is closed. A newer notice from the same program is forecast: Informing global polio eradication efforts through innovative modeling approaches (CDC-RFA-JG-27-0077). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - CGH notices from 2022.

• Total funding$1.8 million
• Expected awards2
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to any type of organization.

N/A

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (47% over five years) went to nonprofits.
• No cost sharing or match is required.

What the grant funds

The Global Polio Eradication Initiative (GPEI) began in 1988 with the objective of wild poliovirus (WPV) eradication and ultimate eradication of all polioviruses, including vaccine-derived polioviruses (VDPV). The Centers for Disease Control and Prevention (CDC) is one of the founding partners of the GPEI, providing technical and financial support (https://polioeradication.org/). Polio eradication remains an agency-wide priority; CDC's Emergency Operations Center (EOC) has been activated since December 2011 to support global polio response activities. The GPEI has made tremendous progress toward global WPV eradication, from 125 countries in 1988 to two countries in 2021. WPV types 2 and 3 have been eradicated and only WPV type 1 (WPV1) remains. Of WHO’s six Regions, only the Eastern Mediterranean Region remains affected. The GPEI faces two major challenges: 1) continued transmission of WPV1 in Pakistan and Afghanistan and 2) increasing number of circulating vaccine-derived poliovirus (cVDPVs) which result from prolonged transmission in under-immunized communities of the live weakened virus from the oral poliovirus vaccine (OPV). GPEI’s newest strategy, Polio Eradication Strategy 2022-2026: Delivering on a Promise, outlines how the partnership intends to address these challenges. Concurrently, GPEI must begin planning now for the future of a polio-free world. Current planning is that within 12 months of certification of WPV eradication, all OPVs will be removed from essential immunization programs (i.e., OPV cessation). The risk of emergence of VDPVs will be highest in the first two years after OPV cessation as intestinal mucosal immunity needed to stop virus transmission wanes. The risk of accidental introduction in communities and the environment by a containment breach from a poliovirus essential facility (PEF), such as a poliovirus vaccine manufacturer, will persist as long as live polioviruses are maintained at facilities. Numerous key questions remain about interrupting cVDPV transmission in the near-term, and the long-term needs of poliovirus surveillance. For cVDPV interruption, the focus is on which factor or combination of factors would optimize field-level response strategies to quickly interrupt transmission and associated costs. Questions on long-term surveillance needs include the optimal mix of poliovirus surveillance systems and activities that will be sustainable yet sensitive to detect emergence of VDPV and associated costs.

Category: Health.

Applying now

This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0077, which is forecast.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.